Mutual of America Capital Management LLC Sells 472 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Mutual of America Capital Management LLC decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 0.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 50,341 shares of the company’s stock after selling 472 shares during the period. Mutual of America Capital Management LLC’s holdings in Vaxcyte were worth $5,752,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Riverview Trust Co purchased a new position in shares of Vaxcyte during the third quarter worth approximately $27,000. Blue Trust Inc. increased its holdings in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the period. Fifth Third Bancorp bought a new stake in Vaxcyte during the 2nd quarter valued at $35,000. J.Safra Asset Management Corp lifted its holdings in shares of Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after buying an additional 526 shares during the period. Finally, Quest Partners LLC purchased a new stake in shares of Vaxcyte in the 2nd quarter worth $70,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Up 0.7 %

Shares of PCVX opened at $87.08 on Wednesday. The company has a 50 day moving average of $109.51 and a two-hundred day moving average of $89.13. The company has a market cap of $10.85 billion, a price-to-earnings ratio of -18.93 and a beta of 1.01. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the firm posted ($0.91) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PCVX. Mizuho lifted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Needham & Company LLC restated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. BTIG Research lifted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Bank of America lifted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $147.50.

Insider Transactions at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at approximately $37,822,574.24. The trade was a 3.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 117,464 shares of company stock worth $12,640,276. Insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.